Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics
Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform
BURNABY, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that it is receiving advisory services and research and development funding of up to $6,659,050 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the implementation and completion of a Phase II randomized, placebo-controlled clinical trial of QBKPN SSI, a first-in-class immune modulator designed to optimize immunity and barrier function in the lungs. The trial (Immunosenescence [IS]-01) will evaluate the efficacy of QBKPN SSI in restoring innate immunity, preventing serious morbidity and mortality from COVID-19 and other respiratory pathogens, and reducing all-cause mortality in the elderly.
BURNABY, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce it has received Health Canada clearance (No Objection Letter) and institutional-level ethics approval to proceed with a randomized placebo-controlled Phase II multicenter trial to assess the effectiveness of QBECO SSI in reducing postoperative immune suppression and improving cancer outcomes in patients with late-stage colorectal cancer undergoing surgical resection of liver metastases. QBECO SSI is a first-in-class innate immune modulator specifically designed to restore innate immune function in the gastrointestinal (GI) tract, including the liver. The study, which is led by gastroenterology (GI) oncology surgeons Dr. Rebecca Auer (Ottawa Hospital Research Institute) and Dr. Paul Karanicolas (Sunnybrook Health Sciences Centre) and managed by the Centre of Clinical Trial Support at the Sunnybrook Research Institute, will enroll patients through a minimum of six academic oncology centers in Ontario.
BURNABY, British Columbia, July 20, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it received clearance (No Objection Letter) from Health Canada to proceed with a randomized placebo-controlled clinical trial of QBKPN, a first-in-class innate immune modulator that enhances lung immunity, in the elderly (Immunosenescence [IS]-01 trial). The clinical trial is designed to assess QBKPN’s effectiveness in restoring innate immunity, the prevention of serious morbidity and mortality from respiratory infections, including COVID-19 and its variants, and reduction in all-cause mortality. With the receipt of Health Canada’s No Objection Letter, the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) has committed additional advisory services and conditional funding to support this important clinical study.
BURNABY, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that data from Qu’s RESTORE clinical trial was presented at the 16th Congress of the European Crohn’s and Colitis Organization (ECCO). Selected for oral presentation, the data was presented on Saturday, July 10th by the study’s Principal Investigator, Dr. Brian Bressler, Director of the Advanced IBD Training Program at the University of British Columbia. The Phase 2 RESTORE study assessed the efficacy of Qu Biologics’ QBECO SSI for the induction and maintenance of clinical and endoscopic response and remission in 20 patients with moderate-to-severe Crohn’s Disease over a 52-week treatment period.
VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and additional research and development funding of up to $1,971,195 funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to quickly move forward the application of Qu’s lung-directed SSI, QBKPN, to prevent and treat COVID-19. This additional funding brings the total project amount that Qu is receiving from NRC IRAP up to $2,200,959, and it comes following promising animal study data showing that QBKPN treatment safely reduced infection with SARS-CoV-2, the virus that causes COVID-19. This new funding will further research and manufacturing, including confirmation that QBKPN protects against new COVID-19 variants, production of QBKPN SSI in Canada in preparation for a COVID-19 clinical trial, expansion of Qu’s research and development teams, and support for a COVID-19 clinical trial application regulatory submission and approval.
Qu Biologics’ RESTORE Trial Selected for Oral Presentation at ECCO 2021
VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to report positive signs of clinical, endoscopic and histologic response in subjects participating in Stage 1 of their Phase 2 RESTORE trial for the treatment of patients with moderate-to-severe Crohn’s disease. These positive signals emerged from a recently completed interim analysis of Stage 1, which is designed to assess the optimal timepoint to measure endoscopic response induction in patients treated with QBECO, Qu’s gastrointestinal-targeted SSI.